BIO BIO RAD LABS INC revenue, earnings and financials
For the quarter ended June 30, 2026, BIO RAD LABS INC reported revenue of $651M (down 0.1% from a year earlier), net income of $371M and diluted EPS of $13.85; over the last four quarters revenue was $2.59B and net income $222M; for the fiscal year ended December 2025 revenue was $2.58B, up 0.7% on the year before.
BIO annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $2.58B, gross profit $1.34B, operating income $47.2M, net income $760M (margin 29.4%), EPS $27.85
- Fiscal year ended Dec 2024: revenue $2.57B, gross profit $1.38B, operating income $269M, net income −$1.84B (margin -71.9%), EPS −$65.36
- Fiscal year ended Dec 2023: revenue $2.67B, gross profit $1.43B, operating income $338M, net income −$637M (margin -23.9%), EPS −$21.82
- Fiscal year ended Dec 2022: revenue $2.80B, gross profit $1.57B, operating income $483M, net income −$3.63B (margin -129.5%), EPS −$121.79
- Fiscal year ended Dec 2021: revenue $2.92B, gross profit $1.64B, operating income $500M, net income $4.25B (margin 145.6%), EPS $140.83
BIO quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $651M (down 0.1% year over year), net income $371M, EPS $13.85
- Quarter ended Mar 31, 2026: revenue $592M (up 1.1% year over year), net income −$527M, EPS −$19.55
- Quarter ended Dec 31, 2025 (from the annual report): revenue $693M (up 3.9% year over year), net income $720M, EPS $26.59
- Quarter ended Sep 30, 2025: revenue $653M (up 0.5% year over year), net income −$342M, EPS −$12.70
- Quarter ended Jun 30, 2025: revenue $652M (up 2.1% year over year), net income $318M, EPS $11.67
- Quarter ended Mar 31, 2025: revenue $585M (down 4.2% year over year), net income $64.0M, EPS $2.29
- Quarter ended Dec 31, 2024: revenue $668M (down 2.0% year over year), net income −$716M, EPS −$25.57
- Quarter ended Sep 30, 2024: revenue $650M (up 2.8% year over year), net income $653M, EPS $23.34
- Quarter ended Jun 30, 2024: revenue $639M (down 6.3% year over year), net income −$2.17B, EPS −$76.26
- Quarter ended Mar 31, 2024: revenue $611M (down 9.8% year over year), net income $384M, EPS $13.45
- Quarter ended Dec 31, 2023: revenue $681M (down 6.7% year over year), net income $350M, EPS $12.14
- Quarter ended Sep 30, 2023: revenue $632M (down 7.1% year over year), net income $106M, EPS $3.64
- Quarter ended Jun 30, 2023: revenue $681M (down 1.4% year over year), net income −$1.16B, EPS −$39.59
- Quarter ended Mar 31, 2023: revenue $677M (down 3.3% year over year), net income $69.0M, EPS $2.32
- Quarter ended Dec 31, 2022: revenue $730M (down 0.3% year over year), net income $828M, EPS $27.78
- Quarter ended Sep 30, 2022: revenue $681M (down 8.9% year over year), net income −$163M, EPS −$5.48
- Quarter ended Jun 30, 2022: revenue $691M (down 3.5% year over year), net income −$925M, EPS −$31.05
- Quarter ended Mar 31, 2022: revenue $700M (down 3.7% year over year), net income −$3.37B, EPS −$112.50
- Quarter ended Dec 31, 2021: revenue $733M, net income −$1.57B, EPS −$52.54
- Quarter ended Sep 30, 2021: revenue $747M, net income $3.93B, EPS $130.02
BIO cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow $532M, share buybacks $296M
- Fiscal year ended Dec 2024: operating cash flow $455M, share buybacks $204M
- Fiscal year ended Dec 2023: operating cash flow $375M, share buybacks $429M
- Fiscal year ended Dec 2022: operating cash flow $194M, share buybacks $216M
- Fiscal year ended Dec 2021: operating cash flow $669M, share buybacks $50.0M
BIO balance sheet
- Jun 30, 2026: cash $517M, total assets $10.3B, total liabilities $3.08B, shareholders' equity $7.17B, long-term debt $803M
- Mar 31, 2026: cash $507M, total assets $9.79B, total liabilities $2.94B, shareholders' equity $6.85B, long-term debt $803M
- Dec 31, 2025: cash $530M, total assets $10.6B, total liabilities $3.12B, shareholders' equity $7.45B, long-term debt $1.20B
- Sep 30, 2025: cash $396M, total assets $9.70B, total liabilities $2.96B, shareholders' equity $6.74B, long-term debt $1.20B
- Jun 30, 2025: cash $369M, total assets $10.2B, total liabilities $3.09B, shareholders' equity $7.13B, long-term debt $1.20B
- Mar 31, 2025: cash $521M, total assets $9.53B, total liabilities $2.85B, shareholders' equity $6.68B, long-term debt $1.20B
- Dec 31, 2024: cash $488M, total assets $9.36B, total liabilities $2.79B, shareholders' equity $6.57B, long-term debt $1.20B
- Sep 30, 2024: cash $410M, total assets $10.6B, total liabilities $3.12B, shareholders' equity $7.49B, long-term debt $1.20B
What is BIO's revenue?
BIO RAD LABS INC reported $2.59B of revenue over its last four quarters, through June 30, 2026.
Is BIO profitable?
Yes. BIO RAD LABS INC earned $222M over the last four quarters.
What is BIO's EPS?
Diluted earnings per share over the last four quarters were $8.19; $13.85 in the latest quarter.